The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been ...

Nearly one in five patients with malignant pleural mesothelioma (MPM) at a Barcelona hospital contracted COVID-19 during the pandemic. In addition, those patients suffered a 75% mortality rate, ...

A new prognostic score in patients with malignant pleural mesothelioma. Background: Chemotherapy is the only option for MPM. Cisplatin + pemetrexed became the standard in the first-line (FL), while ...

Show More Medical Oncology, Hospital Universitari Vall d´Hebron and Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; Thoracic ...

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in ...

Polaris Pharmaceuticals Inc. has submitted the first part of its rolling BLA to the FDA for lead product, ADI-PEG 20, for systemic treatment of patients with malignant pleural mesothelioma with ...

There are several types of malignant mesothelioma. Doctors know which type you have based on where the cells are located and how they're arranged. Malignant pleural mesothelioma. Cancer cells are ...

Separating benign from malignant mesotheliomas can determine patient prognosis but may be a complicated process. Several markers for mesothelioma, which have been developed over the past decade, can ...